Skip to Content

ECTRIMS 2024: New Data Has the Potential to Paving the Way for More Personalised and Effective Treatment Plans

A study presented at ECTRIMS 2024 has identified key biomarkers that can accurately predict disability progression in multiple sclerosis (MS). These findings have the potential to significantly impact MS treatment approaches, enabling the development of more personalized and effective therapeutic strategies tailored to individual patient profiles. 

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top